Publications by authors named "Zhixin Sheng"

Claim this Profile
R
Regulating Crystallization and Carrier Recombination of Quasi-2D Perovskite for Efficient Air-Processed Light-Emitting Diodes.
Yu Tong, Yibo Wang, Heng Qi, Peiyuan Pang, Zhixin Sheng

Nano Lett· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strongly Anchored Dion-Jacobson Perovskite for Efficient Blue Light-Emitting Diodes.
Heng Qi, Yu Tong, Yibo Wang, Yue Liu, Zhixin Sheng

Nano Lett· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: A network meta-analysis.
Zhixin Sheng, Lida Wang

Eur J Haematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs.
Zhixin Sheng, Dianfang Li, Bing Chen, Chunwu Zhao, Wenxing Zhang

Ann Hematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Lida Wang, Zhixin Sheng, Junying Zhang, Jiwu Song, Lili Teng

J Chemother· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An angiosarcoma in the breast associated with Kasabach-Merritt syndrome: Breast Images.
Da Huo, Zhi-Xin Sheng, Gui-Yan Han, Wen-Hui Wang, Li-Ping Wang

Breast J· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
Zhixin Sheng, Shilei Song, Miao Yu, Hongguang Zhu, Anran Gao

Leuk Lymphoma· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of CD4/6 inhibitors, PI3K inhibitors, and mTOR inhibitors for patients with advanced HR+/HER2- Breast cancer: A network meta-analysis of 19 RCTs.
Lida Wang, Huo Da, Xiulian Li, Xuehong Ran, Wei Wu, Zhixin Sheng

Breast J· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2- breast cancer: A meta-analysis of randomized controlled trials.
Liquan Wang, Shuyan Gao, Dianfang Li, Xuehong Ran, Zhixin Sheng

Breast J· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis.
Wenjun Xu, DianFang Li, Yanhua Sun, Xuehong Ran, Baohong Wang, Zhixin Sheng

Eur J Haematol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of asthma with coronary heart disease: A meta analysis of 11 trials.
Lida Wang, Shuyan Gao, Mingdong Yu, Zhixin Sheng, Wei Tan

PLoS One· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
Zhixin Sheng, Yanxia Zhang

Am J Clin Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer.
Zhixin Sheng, Xu Zhu, Yanhua Sun, Yanxia Zhang

Oncotarget· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials.
Zhixin Sheng, Guifang Li, Bin Li, Yanju Liu, Lida Wang

Eur J Haematol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials.
Guifang Li, Shunji Gao, Zhixin Sheng, Bin Li

Chemotherapy· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction Note to: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
Jin Liu, Zhixin Sheng, Yanxia Zhang, Guixin Li

Target Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.
Liping Liu, Ningning Zhao, Wenjun Xu, Zhixin Sheng, Lida Wang

J Hematol Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.
Zhixin Sheng, Guangyu Liu

Hematol Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
Jin Liu, Zhixin Sheng, Yanxia Zhang, Guixin Li

Target Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severity stratification of aplastic anemia.
Cuiai Ren, Yanxiang Li, Jingying Cui, Fengxia Liu, Zhixin Sheng

Chin Med J (Engl)· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer.
Zhixin Sheng, Yanxia Zhang

Med Oncol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
Yandun Zou, Mingzhen Lin, Zhixin Sheng, Shaona Niu

Leuk Lymphoma· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of glycyrrhizin combined with cyclosporine in the treatment of non-severe aplastic anemia.
Cui-ai Ren, Yan-xiang Li, Jing-ying Cui, Zhi-xin Sheng, Xue-hong Ran

Chin Med J (Engl)· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma.
Yandun Zou, Zhixin Sheng, Shaona Niu, Huijuan Wang, Jinming Yu

Leuk Lymphoma· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous treatment with new agents for newly diagnosed multiple myeloma.
Yandun Zou, Zhixin Sheng, Hongkai Lu, Jinming Yu

Anticancer Drugs· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis